IGF2BP1 and lung adenocarcinoma: Further studies demonstrated that IGF2BP1 expression was strongly associated with immune infiltration, immune checkpoint expression, the effectiveness of immunotherapy in LUAD patients, and the incidence, progression, metastasis, and treatment resistance of lung adenocarcinoma.